Today, we put Janux Therapeutics, Inc. (NASDAQ:JANX) in the spotlight for the first time since our initial article on this name earlier this year. There has been a notable increase in buyout speculation since then as well as some significant insider selling in June triggering a revisit. This clinical stage biotech name came public during the huge IPO/SPAC wave of 2020/2021 when interest rates were right near zero thanks to the Federal Reserve. Unlike most stocks birthed during this 'vintage', the shares of Janux Therapeutics are up from the debut. So, what is behind the enthusiasm around this developmental firm?